Spondylitis ankylopoetica (Bechterew-kór): ki dolgozik rajta

Intézményenként egy kártya. Válassz célpontot, és csak az azon dolgozó csoportok maradnak.

• Minden célpont
• IL-17 3
• TNF 2
• JAK 1
• IL-23 1
• NLRP3 0
• STAT3 0
• TLR4 0
• COX-2 0
• IL-6 0
• MAPK 0
• NRF2 0
• PD-1 0
• AKT 0
• AXL 0
• BDNF 0
• CD40 0
• CGRP 0
• CXCR4 0
• ERK 0
• FAK 0
• G6PD 0
• HIF-1 0
• IL-1 0
• IL-15 0
• MEK 0
• NF1 0
• PD-L1 0
• PI3K 0
• PIK3CA 0
• PPAR 0
• PTEN 0
• RANKL 0
• VEGF 0

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-IA

  CANVAS: STREET FURNITURE AS A CANVAS - BEAUTY, INCLUSION AND SUSTAINABILITY IN PUBLIC SPACE

  Ait Austrian Institute of Technology Gmbh· Wien, Ausztria· EU contribution 5 110 818 EUR· until 2030. aug.· 10 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  SAFETY, EFFECTIVENESS AND COST-EFFECTIVENESS OF PROBIOTICS AS ADJUNCT PREVENTIVE THERAPY FOR CHILDHOOD DIARRHOEA AND ANTIMICROBIAL RESISTANCE IN AFRICA: A DOUBLE BLINDED RANDOMIZED CONTROLLED TRIAL (PRoRota)

  Universitetet I Bergen· Bergen, Norvégia· EU contribution 5 299 999 EUR· until 2030. ápr.· 4 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  NEXT-GENERATION SCALABLE AEM ELECTROLYZERS AS SUSTAINABLE HYDROGEN PRODUCTION SYSTEM (NEREUS)

  Antares Electrolysis S.r.l.· Genova, Olaszország· EU contribution 3 999 786 EUR· until 2029. febr.· 7 countries

• European Commission (Horizon Europe) · HORIZON-CSA

  OPERATING OPEN RESEARCH EUROPE AS A NON-PROFIT OPEN ACCESS SCIENTIFIC PUBLISHING SERVICE FOR THE PUBLIC GOOD (ORE 2.0)

  Organisation Europeenne Pour la Recherche Nucleaire· Geneve 23, Svájc· EU contribution 9 996 090 EUR· until 2030. dec.

• European Commission (Horizon Europe) · HORIZON-RIA

  CARBON-NEUTRAL PRODUCTION AND DIRECT FUEL-CELL DEPLOYMENT OF ISOPROPANOL AS ENERGY CARRIER (IsoPROPEL)

  Agencia Estatal Consejo Superior de Investigaciones Cientificas· Madrid, Spanyolország· EU contribution 3 995 636 EUR· until 2029. ápr.· 8 countries

• European Commission (Horizon Europe) · HORIZON-IA

  VALORISATION OF HARVESTED AGROFORESTRY BIOMASS WASTE AS FEEDSTOCK FOR VALUE-ADDED BIO-BASED SOLUTIONS AS A GREEN DEVELOPMENT PATHWAY (HARWASTING)

  Instituto Tecnologico Metalmecanico, Mueble, Madera, Embalaje y Afines-Aidimme· Paterna Valencia, Spanyolország· EU contribution 4 991 329 EUR· until 2029. febr.· 7 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  REPURPOSING FUSIDIC ACID AS A SHORT-COURSE ONCHOCERCA VOLVULUS MACROFILARICIDE: A RANDOMIZED CONTROLLED OPEN-LABEL PARALLEL GROUP INTERVENTION PHASE IIA/B PILOT TRIAL (FAME)

  Liverpool School of Tropical Medicine· Liverpool 3, Egyesült Királyság· EU contribution 5 121 719 EUR· until 2029. febr.· 4 countries

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  INNOVATIVE, SUSTAINABLE AND CIRCULAR PRODUCTION OF PURPLE PHOTOTROPHIC BACTERIA AS HEALTH-PROMOTING INGREDIENT FOR FOOD AND FEED APPLICATIONS (Purple4Life)

  Universite de Mons· Mons, Belgium· EU contribution 3 721 694 EUR· until 2029. máj.· 9 countries

• European Commission (Horizon Europe) · HORIZON-ERC

  MXENES AS THERMAL CATALYSTS. EXPLOITING THE IDEAL PROPERTIES OF CHAMELEONIC MATERIALS (DISCOVERY)

  Universitat Politecnica de Valencia· Valencia, Spanyolország· EU contribution 2 500 000 EUR· until 2029. szept.

• European Commission (Horizon Europe) · HORIZON-JU-RIA

  BREWERS SPENT GRAIN AS MAIN BY-PRODUCT FOR DEVELOPMENT OF NOVEL, HIGH-PERFORMANCE BIO-BASED POLYMERS, POLYMER BLENDS, AND CO-POLYMERS (POLYMEER)

  Universita Degli Studi di Perugia· Perugia, Olaszország· EU contribution 4 878 093 EUR· until 2028. aug.· 8 countries

10 of 19 running projects, newest first. Listed amounts together: 89,0 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

Ebben a nézetben egy vizsgálat sem jelzi, hogy megosztaná a résztvevői adatokat.

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 7
• Mendelian Randomization Analysis 20
• Gene Expression Profiling 12
• Sequence Analysis, RNA 1
• Whole Genome Sequencing 1
• Exome Sequencing 2
• Proteomics 9
• Metabolomics 5
• Flow Cytometry 3
• Magnetic Resonance Imaging 71
• Machine Learning 10
• Deep Learning 8
• Cohort Studies 24
• Genome-Wide Association Study 24

• Predicting disease flares in axial spondyloarthritis using different machine learning models in the METEOR-SpA registry.

  RMD Open, 2026. szept.

• Machine learning integrating immune-related cells, immunoglobulins, and immuno-inflammatory markers identifies risk factors for pulmonary comorbidities in ankylosing spondylitis: stratified analyses by chronic obstructive pulmonary disease and pulmonary nodules.

  Front Immunol, 2026. aug.

• Integrated Transcriptomic and Machine-Learning Analyses Identify Shared Na+ Overload-Related Gene Signatures in Inflammatory Bowel Disease and Ankylosing Spondylitis.

  Genes (Basel), 2026. aug.

• Predicting ankylosing spondylitis disease activity via patient-reported outcome measures: Building prediction models based on machine learning.

  PLoS One, 2026. júl.

• Molecular mechanisms linking cadmium chloride exposure to ankylosing spondylitis: an integrative network-based study.

  Naunyn Schmiedebergs Arch Pharmacol, 2026. máj.

• A multicenter explainable machine learning analysis of autoimmune disease comorbidity in ankylosing spondylitis.

  Front Immunol, 2026. febr.

• Learning from multiple readings for axial spondyloarthritis classification of the sacroiliac joints.

  Sci Rep, 2026. febr.

• Evaluating the performance and acceptability of an artificial intelligence digital health exercise platform in females with and without axial spondyloarthritis: a phase I study.

  Adv Rheumatol, 2026. jan.

• Diagnostic and prognostic performance of artificial intelligence and radiomics in ankylosing spondylitis: a systematic review and meta-analysis.

  J Robot Surg, 2026. jan.

• Identification of cross-diagnostic biomarkers in ankylosing spondylitis and sarcopenia by bioinformatics and machine learning.

  Medicine (Baltimore), 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.